Derya Tilki1, Philipp Mandel2, Flora Seeliger2, Alexander Kretschmer2, Alexander Karl2, Süleyman Ergün3, Michael Seitz4, Christian G Stief2. 1. Department of Urology, Ludwig-Maximilians-University, Klinikum Grosshadern, Munich, Germany; Martini-Clinic Prostate Cancer Center and Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany. Electronic address: d.tilki@uke.de. 2. Department of Urology, Ludwig-Maximilians-University, Klinikum Grosshadern, Munich, Germany. 3. Institute of Anatomy and Cell Biology, University of Würzburg, Würzburg, Germany. 4. Department of Urology, Ludwig-Maximilians-University, Klinikum Grosshadern, Munich, Germany; UroClinic Bogenhausen, Munich, Germany.
Abstract
PURPOSE: We analyzed the impact of salvage lymph node dissection on the prognosis in patients with biochemical recurrence and positive lymph nodes on positron emission tomography/computerized tomography after radical prostatectomy. MATERIALS AND METHODS: We retrospectively analyzed the records of 58 patients who underwent pelvic and/or retroperitoneal salvage lymph node dissection from June 2005 to February 2012. Biochemical response was defined as prostate specific antigen less than 0.2 ng/ml 40 days after salvage treatment. Biochemical recurrence in those with a biochemical response was defined as prostate specific antigen greater than 0.2 ng/ml and increasing. Kaplan-Meier curves were used to assess time to biochemical recurrence, clinical recurrence and cancer specific survival. Cox and binary logistic regressions were used to determine factors influencing clinical recurrence and biochemical response. RESULTS: Median followup after salvage lymph node dissection was 39 months. A total of 13 patients (22.4%) achieved a biochemical response. Only 1 patient remained free of biochemical recurrence during followup. Clinical recurrence developed in 25 patients (48.1%) after salvage treatment. Six patients (10.3%) died of disease, including 4 with indeterminate extralymphatic findings on positron emission tomography/computerized tomography before salvage therapy. The 5-year cancer specific survival rate was 71.1%. Patients with a complete biochemical response showed a trend toward a longer time to clinical recurrence (p = 0.20). Biochemical response did not influence cancer specific survival. CONCLUSIONS: Salvage lymph node dissection in patients with biochemical recurrence and positive lymph nodes on positron emission tomography/computerized tomography led to a biochemical response in a certain proportion. Most patients progressed to biochemical recurrence after salvage treatment but almost half showed no further clinical recurrence. Cancer specific mortality occurred predominantly in patients with prior suspicion of extralymphatic lesions. Salvage lymph node dissection may delay androgen deprivation therapy and clinical recurrence in select patients.
PURPOSE: We analyzed the impact of salvage lymph node dissection on the prognosis in patients with biochemical recurrence and positive lymph nodes on positron emission tomography/computerized tomography after radical prostatectomy. MATERIALS AND METHODS: We retrospectively analyzed the records of 58 patients who underwent pelvic and/or retroperitoneal salvage lymph node dissection from June 2005 to February 2012. Biochemical response was defined as prostate specific antigen less than 0.2 ng/ml 40 days after salvage treatment. Biochemical recurrence in those with a biochemical response was defined as prostate specific antigen greater than 0.2 ng/ml and increasing. Kaplan-Meier curves were used to assess time to biochemical recurrence, clinical recurrence and cancer specific survival. Cox and binary logistic regressions were used to determine factors influencing clinical recurrence and biochemical response. RESULTS: Median followup after salvage lymph node dissection was 39 months. A total of 13 patients (22.4%) achieved a biochemical response. Only 1 patient remained free of biochemical recurrence during followup. Clinical recurrence developed in 25 patients (48.1%) after salvage treatment. Six patients (10.3%) died of disease, including 4 with indeterminate extralymphatic findings on positron emission tomography/computerized tomography before salvage therapy. The 5-year cancer specific survival rate was 71.1%. Patients with a complete biochemical response showed a trend toward a longer time to clinical recurrence (p = 0.20). Biochemical response did not influence cancer specific survival. CONCLUSIONS: Salvage lymph node dissection in patients with biochemical recurrence and positive lymph nodes on positron emission tomography/computerized tomography led to a biochemical response in a certain proportion. Most patients progressed to biochemical recurrence after salvage treatment but almost half showed no further clinical recurrence. Cancer specific mortality occurred predominantly in patients with prior suspicion of extralymphatic lesions. Salvage lymph node dissection may delay androgen deprivation therapy and clinical recurrence in select patients.
Authors: Gargi Kothari; Piet Ost; Patrick Cheung; Pierre Blanchard; Alison C Tree; Nicholas J van As; Simon S Lo; Drew Moghanaki; Andrew Loblaw; Shankar Siva Journal: Curr Oncol Rep Date: 2019-03-27 Impact factor: 5.075
Authors: Andre Abreu; Carlos Fay; Daniel Park; David Quinn; Tanya Dorff; John Carpten; Peter Kuhn; Parkash Gill; Fabio Almeida; Inderbir Gill Journal: BJU Int Date: 2017-01-14 Impact factor: 5.969
Authors: Nieroshan Rajarubendra; Fabio Almeida; Zarko Manojlovic; Chisato Ohe; Nariman Ahmadi; Giovanni Cacciamani; Michael Qiu; Andre Abreu; Jie Cai; Gus Miranda; Mariana C Stern; John Carpten; Peter Kuhn; Mahul B Amin; Parkash S Gill; Manju Aron; Inderbir S Gill Journal: J Urol Date: 2019-02 Impact factor: 7.600
Authors: Alexander Kretschmer; Johanna Milow; Chukwuka Eze; Alexander Buchner; Minglun Li; Thilo Westhofen; Frederik Fuchs; Paul Rogowski; Christian Trapp; Ute Ganswindt; Mathias Johannes Zacherl; Leonie Beyer; Vera Wenter; Peter Bartenstein; Boris Schlenker; Christian G Stief; Claus Belka; Nina-Sophie Schmidt-Hegemann Journal: Front Oncol Date: 2021-06-21 Impact factor: 6.244
Authors: Nicola Fossati; Nazareno Suardi; Giorgio Gandaglia; Carlo A Bravi; Matteo Soligo; R Jeffrey Karnes; Shahrokh Shariat; Antonino Battaglia; Wouter Everaerts; Steven Joniau; Hendrik Van Poppel; Nieroshan Rajarubendra; Inderbir S Gill; Alessandro Larcher; Alexander Mottrie; Maximilian Schmautz; Axel Heidenreich; Almut Kalz; Daniar Osmonov; Klaus-Peter Juenemann; Annika Herlemann; Christian Gratzke; Christian Stief; Francesco Montorsi; Alberto Briganti Journal: Eur Urol Date: 2018-10-06 Impact factor: 24.267
Authors: Yiming Wang; Christian Gratzke; Alexander Tamalunas; Nicolas Wiemer; Anna Ciotkowska; Beata Rutz; Raphaela Waidelich; Frank Strittmatter; Chunxiao Liu; Christian G Stief; Martin Hennenberg Journal: PLoS One Date: 2016-04-12 Impact factor: 3.240